Download PDF
Hamostaseologie 2008; 28(01/02): 62-65
DOI: 10.1055/s-0037-1616923
Original Article
Schattauer GmbH

Gerinnungshemmende Therapie des akuten Koronarsyndroms

UpdateAnticoagulation in acute coronary syndromeAn update
M. Moser
1   Innere Medizin III (Kardiologie), Universität Freiburg
,
C. Bode
1   Innere Medizin III (Kardiologie), Universität Freiburg
› Author Affiliations
Further Information

Publication History

Publication Date:
29 December 2017 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Das akute Koronarsyndrom ist eine der häufigsten kardialen Erkrankungen. Seine Behandlung stützt sich im Wesentlichen auf Koronarintervention und gerinnungshemmende Therapie. Die thrombozytenaggregationshemmende Therapie besteht zurzeit aus Azetylsalizylsäure und Clopidogrel und ggf. periinterventioneller Glykoprotein-IIb/ IIIa-Blockade. Mit Prasugrel steht ein neuer thrombozytenaggregationshemmender Wirkstoff kurz vor der Einführung in die Klinik.

Bei der antithrombotischen Therapie geht die Entwicklung zu Pharmaka mit Anti-Faktor-Xa-Aktivität (z. B. Fondaparinux) oder direkter Antithrombinwirkung (z. B Bivalirudin). In diesem Übersichtsartikel werden die Entwicklungen der vergangenen Monate auf dem Gebiet der gerinnungshemmenden Therapie des akuten Koronarsyndroms diskutiert.

Summary

The acute coronary syndrome (ACS) is one of the most frequent diagnoses in cardiology. The therapeutic cornerstones of ACS are PCI (percutaneous coronary intervention) and inhibition of blood coagulation. Current antiplatelet therapy consists of aspirin in combination with clopidogrel and glycoprotein IIb/IIIa blockade if needed. Prasugel is a new antiplatelet agent that is in the process of being approved for routine clinical use.

In terms of antithrombotic therapy latest developments focus on drugs with anti-factor Xa activity, such as fondaparinux, or direct anti-thrombin activity, such as bivalirudin. This review discusses latest developments in the field of anti-platelet and anti-thrombotic therapy for ACS.

Schlüsselwörter

Akutes Koronarsyndrom - Prasugrel

Keywords

Acute coronary syndrome - prasugel
 

  • References

  • 1 Bruckenberger E. Herzbericht. 2006
    PubMedGoogle Scholar
  • 2 ISIS-2 Second International Study of Infarct Survival) Collaborative Group.. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17 187 cases of suspected acute myocardial infarction: ISIS-2. J Am Coll Cardiol 1988; 12: 3A-13A.
    CrossrefPubMedGoogle Scholar
  • 3 Braunwald E, Antman EM, Beasley JW. et al Committee on the Management of Patients With Unstable Angina.. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. J Am Coll Cardiol 2002; 40: 1366-1374.
    CrossrefPubMedGoogle Scholar
  • 4 Hamm CW. Guidelines: Acute coronary syndrome (ACS). 1: ACS without persistent ST segment elevations. Z Kardiol 2004; 93: 72-90.
    CrossrefPubMedGoogle Scholar
  • 5 Hamm CW. Guidelines: Acute coronary syndrome (ACS). II: Acute coronary syndrome with ST-elevation. Z Kardiol 2004; 93: 324-341.
    CrossrefPubMedGoogle Scholar
  • 6 Bassand JP, Hamm CW, Ardissino D. et al. Task Force for the Diagnosis and Treatment of Non-STSegment Elevation Acute Coronary Syndromes of the European Society of Cardiology. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J 2007; 28: 1598-1660.
    CrossrefPubMedGoogle Scholar
  • 7 Anderson JL, Adams CD, Antman EM. et al. ACC/ AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2007; 116: e148-304.
    CrossrefPubMedGoogle Scholar
  • 8 Angiolillo DJ, Fernandez-Ortiz A, Bernardo E. et al. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol 2007; 49: 1505-1516.
    CrossrefPubMedGoogle Scholar
  • 9 Montalescot G, Sideris G, Meuleman C. et al. A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) trial. J Am Coll Cardiol 2006; 48: 931-938.
    CrossrefPubMedGoogle Scholar
  • 10 Cuisset T, Frere C, Quilici J. et al. Benefit of a 600-mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing coronary stenting. J Am Coll Cardiol 2006; 48: 1339-1345.
    CrossrefPubMedGoogle Scholar
  • 11 Bhatt DL, Flather MD, Hacke W. et al. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol 2007; 49: 1982-1988.
    CrossrefPubMedGoogle Scholar
  • 12 Silber S, Böhm M, Gottwick M. et al. Akutes Herzinfarktrisiko bei mangelnder Clopidogeleinnahme nach Stentimplantation. Dtsch Ärztebl 2006; 103: A2863.
    PubMedGoogle Scholar
  • 13 TRITON TIMI 38. Oral presentation. 2007; AHA scientific sessions Orlando.
    PubMed
  • 14 Moliterno DJ, Chan AW. Glycoprotein IIb/IIIa inhibition in early intent-to-stent treatment of acute coronary syndromes: EPISTENT, ADMIRAL, CADILLAC, and TARGET. J Am Coll Cardiol 2003; 41: 49S-54S.
    CrossrefPubMedGoogle Scholar
  • 15 Stone GW, Bertrand ME, Moses JW. et al. Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY Timing trial. JAMA 2007; 297: 591-602.
    CrossrefPubMedGoogle Scholar
  • 16 Ellis S. The FINESSE trial. Oral presentation. 2007 ESC Meeting Vienna.
    PubMedGoogle Scholar
  • 17 00. Primary versus tenecteplase-facilitated percutaneous coronary intervention in patients with STsegment elevation acute myocardial infarction (ASSENT-4 PCI): randomised trial. Lancet 2006; 367: 569-578.
    CrossrefPubMedGoogle Scholar
  • 18 Giugliano RP, Newby LK, Harrington RA. et al. The early glycoprotein IIb/IIIa inhibition in non- ST-segment elevation acute coronary syndrome (EARLY ACS) trial: a randomized placebo-controlled trial evaluating the clinical benefits of early front-loaded eptifibatide in the treatment of patients with non-ST-segment elevation acute coro- nary syndrome – study design and rationale. Am Heart J 2005; 149: 994-1002.
    CrossrefPubMedGoogle Scholar
  • 19 Tricoci P, Peterson ED, Chen AY. et al. Timing of glycoprotein IIb/IIIa inhibitor use and outcomes among patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention (results from CRUSADE). Am J Cardiol 2007; 99: 1389-1393.
    CrossrefPubMedGoogle Scholar
  • 20 Ryan JW, Peterson ED, Chen AY. et al. Optimal timing of intervention in non-ST-segment elevation acute coronary syndromes: insights from the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines) Registry. Circulation 2005; 112: 3049-3057.
    CrossrefPubMedGoogle Scholar
  • 21 FRagmin and Fast Revascularisation during In- Stability in Coronary artery disease Investigators.. Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. Lancet 1999; 354: 708-715.
    CrossrefPubMedGoogle Scholar
  • 22 Brieger D, Van de Werf F, Avezum A. et al. Interactions between heparins, glycoprotein IIb/IIIa antagonists, and coronary intervention. The Global Registry of Acute Coronary Events (GRACE). Am Heart J 2007; 153: 960-969.
    CrossrefPubMedGoogle Scholar
  • 23 Mehta SR, Granger CB, Eikelboom JW. et al. Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial. J Am Coll Cardiol 2007; 50: 1742-1751.
    CrossrefPubMedGoogle Scholar
  • 24 Yusuf S, Mehta SR, Chrolavicius S. et al. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA 2006; 295: 1519-1530.
    CrossrefPubMedGoogle Scholar
  • 25 Stone GW, McLaurin BT, Cox DA. et al. Bivalirudin for patients with acute coronary syndromes. N Engl J Med 2006; 355: 2203-2216.
    CrossrefPubMedGoogle Scholar
  • 26 Stone GW. HORIZONS-AMI. Oral presentation TCT meeting Washington, DC. 2007.
    PubMedGoogle Scholar